EP2445904 - 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS [Right-click to bookmark this link] | |||
Former [2012/18] | NOVEL GPR 119 AGONISTS | ||
[2012/49] | Status | No opposition filed within time limit Status updated on 18.07.2014 Database last updated on 19.10.2024 | Most recent event Tooltip | 12.10.2018 | Lapse of the patent in a contracting state New state(s): AL | published on 14.11.2018 [2018/46] | Applicant(s) | For all designated states Cadila Healthcare Limited Zydus Tower Satellite Cross Roads Ahmedabad 380 015, Gujarat / IN | [2012/18] | Inventor(s) | 01 /
PINGALI, Harikishore Cadila Healthcare Limited Zydus Tower Satellite Cross Roads Ahmedabad 380 015 / IN | 02 /
ZAWARE, Pandurang Cadila Healthcare Limited Zydus Tower Satellite Cross Roads Ahmedabad 380 015 / IN | 03 /
JAIN, Mukul Cadila Healthcare Limited Zydus Tower Satellite Cross Roads Ahmedabad 380 015 / IN | [2012/18] | Representative(s) | Fagerlin, Heléne Zacco Sweden AB P.O. Box 5581 114 85 Stockholm / SE | [2013/37] |
Former [2012/18] | Fagerlin, Heléne Albihns.Zacco Valhallavägen 117 Box 5581 114 85 Stockholm / SE | Application number, filing date | 10747954.5 | 17.06.2010 | WO2010IN00418 | Priority number, date | IN2009MUM1458 | 18.06.2009 Original published format: IN MU14582009 | [2012/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010146605 | Date: | 23.12.2010 | Language: | EN | [2010/51] | Type: | A1 Application with search report | No.: | EP2445904 | Date: | 02.05.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.12.2010 takes the place of the publication of the European patent application. | [2012/18] | Type: | B1 Patent specification | No.: | EP2445904 | Date: | 11.09.2013 | Language: | EN | [2013/37] | Search report(s) | International search report - published on: | EP | 23.12.2010 | Classification | IPC: | C07D411/12, C07D411/14, C07D413/14, C07D417/14, A61K31/4535, A61K31/454, A61K31/506 | [2012/18] | CPC: |
C07D411/12 (EP,KR,US);
A61K31/4545 (KR);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/10 (EP);
A61P43/00 (EP);
A61P9/10 (EP);
C07D411/14 (EP,KR,US);
C07D413/14 (EP,US);
C07D417/14 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/18] | Extension states | BA | 10.01.2012 | ME | 10.01.2012 | RS | 10.01.2012 | Title | German: | 1,3,2-DIOXATHIAN-2-OXID DERIVATE UND IHRE VERWENDUNG ALS GPR 119 AGONISTEN | [2012/49] | English: | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | [2012/49] | French: | DÉRIVÉS DE 1,3,2-DIOXATHIAN-2-OXIDE ET LEUR UTILISATION EN TANT QU'AGONISTES DU RÉCEPTEUR GPR 119 | [2012/49] |
Former [2012/18] | NEUE GPR119-AGONISTEN | ||
Former [2012/18] | NOVEL GPR 119 AGONISTS | ||
Former [2012/18] | NOUVEAUX AGONISTES DE GPR 119 | Entry into regional phase | 10.01.2012 | National basic fee paid | 10.01.2012 | Designation fee(s) paid | 10.01.2012 | Examination fee paid | Examination procedure | 19.01.2011 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 10.01.2012 | Examination requested [2012/18] | 10.07.2012 | Amendment by applicant (claims and/or description) | 28.11.2012 | Communication of intention to grant the patent | 20.03.2013 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 20.03.2013 | Fee for grant paid | 20.03.2013 | Fee for publishing/printing paid | 11.04.2013 | Communication of intention to grant the patent | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.11.2012 | Opposition(s) | 12.06.2014 | No opposition filed within time limit [2014/34] | Fees paid | Renewal fee | 20.06.2012 | Renewal fee patent year 03 | 20.06.2013 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 17.06.2010 | AL | 11.09.2013 | AT | 11.09.2013 | BE | 11.09.2013 | BG | 11.09.2013 | CY | 11.09.2013 | CZ | 11.09.2013 | DK | 11.09.2013 | EE | 11.09.2013 | ES | 11.09.2013 | FI | 11.09.2013 | HR | 11.09.2013 | IT | 11.09.2013 | LT | 11.09.2013 | LV | 11.09.2013 | MC | 11.09.2013 | MK | 11.09.2013 | MT | 11.09.2013 | NL | 11.09.2013 | PL | 11.09.2013 | RO | 11.09.2013 | SE | 11.09.2013 | SI | 11.09.2013 | SK | 11.09.2013 | SM | 11.09.2013 | TR | 11.09.2013 | NO | 11.12.2013 | GR | 12.12.2013 | IS | 11.01.2014 | PT | 13.01.2014 | [2018/46] |
Former [2018/30] | HU | 17.06.2010 | |
AT | 11.09.2013 | ||
BE | 11.09.2013 | ||
BG | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
MC | 11.09.2013 | ||
MK | 11.09.2013 | ||
MT | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
SM | 11.09.2013 | ||
TR | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2016/33] | HU | 17.06.2010 | |
AT | 11.09.2013 | ||
BE | 11.09.2013 | ||
BG | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
MC | 11.09.2013 | ||
MT | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
SM | 11.09.2013 | ||
TR | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2016/32] | HU | 17.06.2010 | |
AT | 11.09.2013 | ||
BE | 11.09.2013 | ||
BG | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
MC | 11.09.2013 | ||
MT | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
SM | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2016/28] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
BG | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
MC | 11.09.2013 | ||
MT | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
SM | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2016/22] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
MC | 11.09.2013 | ||
MT | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
SM | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2016/16] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
MC | 11.09.2013 | ||
MT | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2015/09] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
MC | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2014/41] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
DK | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2014/38] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
IT | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2014/28] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
PT | 13.01.2014 | ||
Former [2014/24] | AT | 11.09.2013 | |
BE | 11.09.2013 | ||
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
EE | 11.09.2013 | ||
ES | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
NL | 11.09.2013 | ||
PL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
Former [2014/23] | BE | 11.09.2013 | |
CY | 11.09.2013 | ||
CZ | 11.09.2013 | ||
EE | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
NL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
SK | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
IS | 11.01.2014 | ||
Former [2014/22] | BE | 11.09.2013 | |
CY | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
NL | 11.09.2013 | ||
RO | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
Former [2014/18] | BE | 11.09.2013 | |
CY | 11.09.2013 | ||
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
Former [2014/12] | CY | 21.08.2013 | |
FI | 11.09.2013 | ||
HR | 11.09.2013 | ||
LT | 11.09.2013 | ||
LV | 11.09.2013 | ||
SE | 11.09.2013 | ||
SI | 11.09.2013 | ||
NO | 11.12.2013 | ||
GR | 12.12.2013 | ||
Former [2014/10] | CY | 21.08.2013 | |
HR | 11.09.2013 | ||
LT | 11.09.2013 | ||
SE | 11.09.2013 | ||
NO | 11.12.2013 | ||
Former [2014/09] | HR | 11.09.2013 | |
LT | 11.09.2013 | ||
SE | 11.09.2013 | ||
NO | 11.12.2013 | ||
Former [2014/08] | LT | 11.09.2013 | |
NO | 11.12.2013 | ||
Former [2014/07] | NO | 11.12.2013 | Cited in | International search | [I]WO2004065380 (ARENA PHARM INC [US], et al) [I] 1,3,4,8,9,12,13,18,20-25,27-31 * page 213 - page 217; claim 1 * * page 90, line 9 - page 92 *; | [I]WO2005007647 (ARENA PHARM INC [US], et al) [I] 1,3,5,8,9,12,13,19-25,27-31 * page 222 - page 226; claim 1 * * page 127, line 30 - page 132, line 4 *; | [I]WO2008083238 (METABOLEX INC [US], et al) [I] 1,3,4,8,9,12,13,18,20-25,27-31 * page 183 - page 184; claim 1 * * page 7, line 26 - line 31 * * page 192; claim 50 *; | [A]WO2009038974 (IRM LLC, et al) [A] 1,2,4-11,14-19,21-31 * page 213 - page 214; claim 1 ** page 230; claims 12,13 * | by applicant | US6468756 | - ROTWEIN, R. ET AL., N. ENGL. J. MED., (1983), vol. 308, pages 65 - 71 | - RIMOIN, D. L., Emery and Rimoin's Principles and Practice of Medical Genetics 3rd Ed., (1996), vol. 1, pages 1401 - 1402 | - LE STUNFF ET AL., DIABETES, (1989), vol. 43, pages 696 - 702 | - PEDERSON, P. DIAB. METAB. REV., (1989), vol. 5, pages 505 - 509 | - BRANCATI, F. L. ET AL., ARCH. INTERN. MED., (1999), vol. 159, pages 957 - 963 | - HILL, J. O. ET AL., SCIENCE, (1998), vol. 280, pages 1371 - 1374 | - ENDOCRINOLOGY, vol. 148, no. 6, pages 2601 - 2609 |